3-(tert-butyl)-5-(hexylthio)-4H-1,2,4-triazole | 1353654-30-4

• 分子结构分类: 有机化合物 - 有机硫化合物 - 硫醚类
• 英文名称: 3-(tert-butyl)-5-(hexylthio)-4H-1,2,4-triazole
• 英文别名: 5-tert-butyl-3-hexylsulfanyl-1H-1,2,4-triazole
• CAS: 1353654-30-4
• 化学式: C₁₂H₂₃N₃S
• mdl: MFCD25958274
• 分子量: 241.401
• InChiKey: LWQKHPRCNOMZEK-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.9
• 重原子数：
  16
• 可旋转键数：
  7
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.833
• 拓扑面积：
  66.9
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  1-trimethylacetyl-3-thiosemicarbazide 在 三乙胺 、 sodium hydroxide 作用下， 以 水 、 乙腈 为溶剂， 反应 5.0h， 生成 3-(tert-butyl)-5-(hexylthio)-4H-1,2,4-triazole
  参考文献：
  名称：

  3-Mercapto-1,2,4-triazoles and N-acylated thiosemicarbazides as metallo-β-lactamase inhibitors

  摘要：

  The production of beta-lactamases is an effective strategy by which pathogenic bacteria can develop resistance against beta-lactam antibiotics. While inhibitors of serine-beta-lactamases are widely used in combination therapy with b-lactam antibiotics, there are no clinically available inhibitors of metallo-beta-lactamases (MBLs), and so there is a need for the development of such inhibitors. This work describes the optimisation of a lead inhibitor previously identified by fragment screening of a compound library. We also report that thiosemicarbazide intermediates in the syntheses of these compounds are also moderately potent inhibitors of the IMP-1 MBL from Pseudomonas aeruginosa. The interactions of these inhibitors with the active site of IMP-1 were examined using in silico methods. (C) 2011 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2011.10.116

文献信息

• 3-Mercapto-1,2,4-triazoles and N-acylated thiosemicarbazides as metallo-β-lactamase inhibitors
  作者：Faridoon、Waleed M. Hussein、Peter Vella、Nazar Ul Islam、David L. Ollis、Gerhard Schenk、Ross P. McGeary

  DOI：10.1016/j.bmcl.2011.10.116

  日期：2012.1

  The production of beta-lactamases is an effective strategy by which pathogenic bacteria can develop resistance against beta-lactam antibiotics. While inhibitors of serine-beta-lactamases are widely used in combination therapy with b-lactam antibiotics, there are no clinically available inhibitors of metallo-beta-lactamases (MBLs), and so there is a need for the development of such inhibitors. This work describes the optimisation of a lead inhibitor previously identified by fragment screening of a compound library. We also report that thiosemicarbazide intermediates in the syntheses of these compounds are also moderately potent inhibitors of the IMP-1 MBL from Pseudomonas aeruginosa. The interactions of these inhibitors with the active site of IMP-1 were examined using in silico methods. (C) 2011 Elsevier Ltd. All rights reserved.